Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Lining up for a nightclub in Copenhagen. Photo: Olafur Steinar Gestsson/Ritzau Scanpix/AFP via Getty

After 18 months of wondering when this will all be over, it's increasingly clear that there will never be a moment of victory for vaccines against variants or humanity against the virus.

The big picture: Case counts remain stubbornly high even where just about everyone who wants a shot has had one. Countries like Australia and New Zealand that had sought to keep out COVID-19 altogether are now learning to live with the virus.

  • The world map is a checkerboard of varying pandemic restrictions, border policies and case counts. The daily global tallies of cases and deaths are around where they were one year ago.

The question: What would finally "beating" COVID-19 actually look like?

Between the lines: According to Jeremy Farrar, a leading authority on infectious diseases and director of the Wellcome Trust, it looks like Denmark.

  • The government there has lifted all restrictions, thanks primarily to a high vaccination rate (76% of the population and 87% of over-12s). The virus is still spreading, one to two Danes are dying each day on average. But serious cases are relatively rare.
  • "This virus will be here, I think, forever," Farrar said. "We won't get to zero deaths."
  • But with near-universal vaccination, natural immunity, and better testing and treatments (as well as ready access to booster shots and second-generation vaccines down the line), wealthy countries can reach a point where the danger is limited.

The flipside: With a lower vaccination rate and high levels of migration, the U.S. will have "a bumpier course," Farrar said.

  • Then there are countries like India, which has given one dose to nearly half its population but has 700 million people still to go — not to mention Afghanistan or the Democratic Republic of the Congo, where hardly anyone has had a first shot.
  • Australia, New Zealand and some Southeast Asian countries that have never had major outbreaks also face "a bumpy exit" because they have little natural immunity and, thus, "their only way of exiting is really close to 100% vaccination."

Looming over all of this is the threat from variants.

  • "If you wanted to conduct an experiment of how to encourage this virus to go down a variant pathway, it would be to have ... some countries with very high vaccine uptake, some with very low, some countries with a lot of natural immunity, some countries with little natural immunity," Farrar says.
  • "We're giving an evolutionary advantage to this virus, which I hope it doesn't exploit."

Of note: Farrar, who serves on the scientific body that advises the United Kingdom's government, thinks countries like the U.K. should therefore offer a third dose to those who are immunosuppressed or otherwise particularly vulnerable, but otherwise opt for the "benevolent self-interest" of sharing doses globally.

  • The vaccines are still serving their main purpose of preventing hospitalizations and deaths, he contends, but "the domestic pressures, driven in some degree by fear, would be to vaccinate all of us a third time, a fourth time, a fifth time."
  • Farrar likens the booster dilemma to debates on climate action.

The bottom line: Farrar envisions a future in which, as with car accidents, COVID-19 will be an unfortunate fact of life.

  • It won't be possible to eliminate deaths, but it will be possible to limit them, "and that will be a trade-off that society comes to accept."
  • Denmark seems to have reached that point. The rest of the world has a ways to go.

Go deeper

Oct 20, 2021 - World

Gates Foundation to send $120 million of COVID antiviral pills to lower-income countries

Illustration: Aïda Amer/Axios

The Bill & Melinda Gates Foundation said Wednesday it will funnel up to $120 million worth of molnupiravir, an experimental antiviral COVID-19 treatment from Merck, to lower-income countries.

Why it matters: The foundation and others see the antiviral pill's promising results against severe COVID-19 and easy distribution as a way to target countries with low vaccination rates.

14 hours ago - Health

FDA authorizes mix-and-match for COVID booster shots

Photo: Francine Orr/Los Angeles Times via Getty Images

The Food and Drug Administration (FDA) on Wednesday gave its approval for Americans to get booster shots that are different from the COVID vaccine they initially received.

Why it matters: The recommendation from the FDA, which also authorized booster shots for people who received Moderna and Johnson & Johnson vaccines on Wednesday, paves the way for an expansion of booster shots.

22 hours ago - Health

White House unveils plan to "quickly" vaccinate kids ages 5-11

Charles Muro, 13, is inoculated at Hartford Healthcare's mass vaccination center at the Connecticut Convention Center in Hartford, Conn. Photo: Joseph Prezioso/AFP via Getty Images

The White House on Wednesday released its plan to vaccinate children between the ages of five and 11, pending authorization from the Food and Drug Administration of the first COVID-19 shot for that age group.

The big picture: The White House said it has secured enough vaccine supply to equip more than 25,000 pediatric and primary care offices, hundreds of school and community health clinics, as well as tens of thousands of pharmacies, to administer the shots.